NASDAQ:CRNXCrinetics Pharmaceuticals Stock Price, Forecast & News

Crinetics Pharmaceuticals' stock was trading at $15.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CRNX shares have increased by 5.4% and is now trading at $16.34. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) announced its quarterly earnings data on Friday, May, 8th. The company reported ($0.71) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.63) by $0.08. The business earned $0.07 million during the quarter. View Crinetics Pharmaceuticals' earnings history.

3 brokerages have issued twelve-month target prices for Crinetics Pharmaceuticals' stock. Their forecasts range from $30.00 to $38.00. On average, they expect Crinetics Pharmaceuticals' stock price to reach $35.00 in the next year. This suggests a possible upside of 114.2% from the stock's current price. View analysts' price targets for Crinetics Pharmaceuticals.

News headlines about CRNX stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Crinetics Pharmaceuticals earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutCrinetics Pharmaceuticals.

Some companies that are related to Crinetics Pharmaceuticals include Prestige Consumer Healthcare (PBH), Principia Biopharma (PRNB), TG Therapeutics (TGTX), IGM Biosciences (IGMS), Eidos Therapeutics (EIDX), SAGE Therapeutics (SAGE), Pacira Biosciences (PCRX), Madrigal Pharmaceuticals (MDGL), Aurinia Pharmaceuticals (AUPH), Epizyme (EPZM), Xencor (XNCR), Corcept Therapeutics (CORT), Zymeworks (ZYME), Heron Therapeutics (HRTX) and Ligand Pharmaceuticals (LGND). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include Arbutus Biopharma (ABUS), Axsome Therapeutics (AXSM), Biohaven Pharmaceutical (BHVN), Crispr Therapeutics (CRSP), Fate Therapeutics (FATE), Immunomedics (IMMU), SCYNEXIS (SCYX), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD) and Apellis Pharmaceuticals (APLS).

(CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

Crinetics Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vivo Capital LLC (10.11%), RA Capital Management L.P. (5.97%), 5AM Venture Management LLC (7.58%), BlackRock Inc. (2.94%), Janus Henderson Group PLC (1.50%) and Burrage Capital Management LLC (0.86%). Company insiders that own Crinetics Pharmaceuticals stock include Alan Seth Krasner, Life Sciences Maste Perceptive, Matthew K Fust, Ventures Iv LP 5Am, Vivo Capital Fund Viii, LP and Vivo Capital Viii, Llc. View institutional ownership trends for Crinetics Pharmaceuticals.

CRNX stock was sold by a variety of institutional investors in the last quarter, including 5AM Venture Management LLC, Morgan Stanley, Victory Capital Management Inc., Victory Capital Management Inc., BlackRock Inc., UBS Group AG, Alps Advisors Inc., and Hershey Trust Co.. Company insiders that have sold Crinetics Pharmaceuticals company stock in the last year include Matthew K Fust, Ventures Iv LP 5Am, and Vivo Capital Viii, Llc. View insider buying and selling activity for Crinetics Pharmaceuticals.

CRNX stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, RA Capital Management L.P., Burrage Capital Management LLC, Geode Capital Management LLC, Alliancebernstein L.P., Janus Henderson Group PLC, BNP Paribas Arbitrage SA, and Citigroup Inc.. Company insiders that have bought Crinetics Pharmaceuticals stock in the last two years include Alan Seth Krasner, Life Sciences Maste Perceptive, and Vivo Capital Viii, Llc. View insider buying and selling activity for Crinetics Pharmaceuticals.

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CRNX stock can currently be purchased for approximately $16.34.

Crinetics Pharmaceuticals has a market capitalization of $536.77 million and generates $1.19 million in revenue each year. The company earns $-50,420,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Crinetics Pharmaceuticals employs 47 workers across the globe.

The official website for Crinetics Pharmaceuticals is www.crinetics.com.

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected]